evenfolio

Consumer Services · NSE: MEDPLUS

Medplus Health Services

Q2 FY27 earnings highlights, from the results presentation

Price as of 16 Nov 2026
618.60−0.10%

Q2 FY27 · From the investor presentation

Read the filing on NSEFiling

166​storesNet store additions · Pharmacy · Q2 FY27Slides · p. 13
5,642​storesStore count · Pharmacy · Sep-26Slides · p. 8
712​storesStores added in 12 months · Pharmacy · last 12 monthsSlides · p. 11
53​storesStore closures and conversions · Pharmacy · Q2 FY27Slides · p. 13
M.Cap
₹7,432Cr
P/E
35.2×
1Y return
−20.82%
From 52W high
−39.5%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue2,0371,679+21.3%1,880+8.4%
EBITDA170149+14.2%133+27.6%
EBITDA margin8.3%8.9%-51 bps7.1%+126 bps
PBTProfit before tax7069+1.8%42+67.5%
Net profit5656+1.0%33+69.0%
EPS (₹)4.724.62+2.2%2.76+71.0%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.

More figures from the presentation

Pharmacy · Capacity
219​storesGross store additions · Q2 FY27
“• 219 gross additions”
Slidesp. 5
Beyond Tier-One · Capacity
101​storesNet store additions beyond Tier-One · Q2 FY27
“• 101 net additions beyond Tier-One”
Slidesp. 5
Pharmacy · Capacity
312​storesNet store additions · H1 FY27
“312 Store Net Additions Stores > 12 months”
Slidesp. 7
Pharmacy · Capacity
441​storesGross store additions · H1 FY27
“• 441 gross additions”
Slidesp. 7
Beyond Tier-One · Capacity
226​storesNet store additions beyond Tier-One · H1 FY27
“• 226 net additions beyond Tier-One”
Slidesp. 7
Private label · Other
1,750​SKUsPrivate label SKUs
“MedPlus has a curated private label range of 1750+ SKUs. From these, we will:”
Slidesp. 10

In short

  1. 01Q2 FY27 revenue was Rs 20,371.1m, up 21.3% year on year; PAT was Rs 560.7m, up 1.0%.
  2. 02Gross margin was 25.1%, 110 bps lower year on year.
  3. 03Pharmacy operating EBITDA margin was 4.4% and diagnostics 23.8% in Q2 FY27.
  4. 04Net store additions were 166 in the quarter, taking the network to 5,642 stores.
  5. 05Stores older than 12 months grew revenue 13.2% with 11.7% store-level EBITDA margin.
  6. 06Operating cash flow was 37.7% of operating EBITDA; closing cash and investments Rs 5,439m.

Segments

Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA margin: pharmacy 4.4%, diagnostics 23.8%, company 4.8%

Slides · p. 18
“Operating EBITDA 3.2% 17.8% -10.6% 3.5% 4.4% 23.8% -8.6% 4.8%”

Pharmacy Retail, Diagnostic: Q2 FY27 operating EBITDA: pharmacy Rs 885.4m, diagnostics Rs 97.9m

Slides · p. 18
“Operating EBITDA 588.1 65.9 (2.8) 651.2 885.4 97.9 (2.2) 981.1”

Stores > 12 months: Older stores: 13.2% revenue growth over Q2 FY26

Slides · p. 5
“• 13.2% revenue growth over Q2FY26”

Stores > 12 months: H1 FY27: older stores grew revenue 14.9%

Slides · p. 7
“• 14.9% revenue growth over H1FY26”

Plan to grow further in cities with market leadership, Metro and Tier-One first

Slides · p. 10
“• Further grow in cities where we have market leadership. Metro and Tier - One followed”

Margins and costs

Gross margin 25.1% in Q2 FY27, lower by 110 bps yoy

Slides · p. 5
“25.1% GM%, lower by 110 bps yoy,”

Stores > 12 months: Stores older than 12 months: 11.7% store level EBITDA margin

Slides · p. 5
“• 11.7% Store Level EBITDA margin”

Private label share 0.6% lower than in Q2 FY26

Slides · p. 5
“0.6% decrease in private label over”

Q2 FY27 finance costs Rs 366.2m, up 27.1% yoy

Slides · p. 17
“Finance Costs (288.2) (332.7) (366.2) 27.1% 10.1% (561.8) (698.9) 24.4%”

Q2 FY27 rental expenses Rs 807.5m, up 19.7% yoy

Slides · p. 17
“Rental Expenses 674.9 773.9 807.5 19.7% 4.3% 1,316.7 1,581.4 20.1%”

Debt and working capital

Operating cash flow was 37.7% of operating EBITDA in Q2 FY27

Slides · p. 5
“• 37.7% OCF/ Operating EBITDA”

Closing cash, bank balance and investments of Rs 5,439m

Slides · p. 5
“₹ 5,439m closing cash, bank balance”

Rs 358m withdrawn from fixed deposits/investments during the quarter

Slides · p. 23
“3. Additionally, during the quarter we have withdrawn ₹358m from fixed deposit/investments”

Net working capital at 54 days as of Sep-26

Slides · p. 22
“NWC (days) 53 53 53 54 54”

H1 FY27 operating cash flow was 99.4% of operating EBITDA

Slides · p. 7
“• 99.4% OCF/ Operating EBITDA”

Other

Q2 FY27 revenue Rs 20,371.1m, up 21.3% yoy and 8.4% qoq; H1 revenue up 21.6%

Slides · p. 17
“Revenue 16,793.3 18,796.0 20,371.1 21.3% 8.4% 32,219.6 39,167.1 21.6%”

Q2 FY27 PAT Rs 560.7m, up 1.0% yoy; H1 FY27 PAT Rs 892.4m, down 8.8%

Slides · p. 17
“PAT 555.0 331.7 560.7 1.0% 69.1% 978.5 892.4 -8.8%”

Company operating EBITDA Rs 981.1m in Q2 FY27, up 10.7% yoy and 50.7% qoq

Slides · p. 17
“Operating EBITDA 886.5 651.2 981.1 10.7% 50.7% 1,614.6 1,632.3 1.1%”

Stores > 12 months: Older stores: 72.0% store level operating ROCE

Slides · p. 5
“• 72.0% Store Level Operating ROCE”

Store level unit economics with ROCE of over 70%

Slides · p. 4
“with ROCE of over 70%”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools